. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Vascul Pharmacol. 2008 Apr 3;49(1):6–13. doi: 10.1016/j.vph.2008.03.005

Table 3.

Maximum contraction and estimated EC₅₀ values for ET-1 (10 pM – 100 nM) - induced contraction in thoracic aorta from WT and sl/sl rats under control conditions, ET_A receptor blockade, ET_B receptor blockade and ET_A plus ET_B receptor blockade.

	Aorta WT		Aorta sl/sl

Treatment	Max contraction [% PE (10 μM)]	EC₅₀ (nM)	Max contraction [% PE (10 μM)]	EC₅₀ (nM)
Vehicle	149±10	11.70±1.31	148±9	12.36±1.23
Atrasentan (10 nM)	92±22^* ^†	44.00±0.5^* ^†	50±19^* ^†	45.73±2.27^* ^†
BQ-788 (100 nM)	176±25	13.51±2.26	137±18	10.97±1.00
Atrasentan (10 nM) + BQ-788 (100 nM)	81±16^* ^†	45.68±3.72^* ^†	65±21^* ^†	48.56±0.83^* ^†

Data are represented as mean ± S.E.M. Atrasentan, ET_A receptor antagonist; BQ-788, ET_B receptor antagonist; PE, phenylephrine; WT, homozygous wildtype rats; sl/sl, homozygous ET_B receptor deficient rats.

represents a statistically significant difference from control (p<0.05)

^†

represents a statistically significant difference from BQ-788 (p<0.05).